107. Fighting infectious diseases with biologics, Paul Garofolo, Co-founder & CEO, Locus Biosciences
Biotech 2050 Podcast
00:00
Indication Selection Frameworks - What You Learned From Venture Discussions Along the Way
Koli was certainly where we had our biggest jump. When we really worked down the ekoli space, there were really sort of two areas to go after that made s for our technology. We looked at how far was the tech, what was the commercial opportunity? What was the regulatory path to get thered? And we felt that recurrent erinary track infections were the right place to be. There's about two million recurrent u t is in the country per year. That's a patient population that brings us back to the good old days,. you know, not oran drug designations, but, you know, millions and millions of patients.
Transcript
Play full episode
